Overview
Type
Deemed Public Limited Company
Revenue
$36.684701 million
Category
Global Quality Biosimilars
Formycon is a leading, independent developer of high-quality follow-on products for biopharmaceutical medicines known as biosimilars. The company focuses on treatments in ophthalmology, immunology and on other key chronic diseases, covering the entire value chain from technical development to the clinical phase III as well as the preparation of dossiers for marketing approval. With its biosimilars, Formycon is making a major contribution towards providing as many patients as possible with access to vital and affordable medicines. Formycon currently has four biosimilars in development. What are Biosimilars? Since their introduction in the 1980s, biopharmaceuticals have revolutionized the treatment of serious diseases such as cancer, diabetes, rheumatoid arthritis, multiple sclerosis and eye diseases. In the coming years, many of these biotech drugs will lose their patent protection – and by 2020, medications with revenues of more than USD 100 billion will be off patent. Biosimilars are follow-on versions of biopharmaceuticals, for which exclusivity has expired. They are approved via stringent regulatory pathways in highly regulated markets (such as EU, US, Japan, Canada, Australia) based on proven similarity of the biosimilar with the originator biopharmaceutical reference product. While the global market for biosimilars is currently more than USD 5.0 billion, industry experts expect this figure to grow up to USD 30 billion by the year 2025. Contact: Formycon AG Fraunhoferstr. 15 82152 Martinsried/Planegg Germany phone +49 (0) 89 - 86 46 67 100 fax + 49 (0) 89 - 86 46 67 110 [email protected] // www.formycon.com Formycon provides formulation and analytical services to the biopharmaceutical industry. Formycon AG is a biopharmaceutical company with more than twelve years experience in product development. The company's activities focus on developing and marketing "biosimilars" - biopharmaceuticals which are similar to existing drugs for which patent protection is expiring - as well as the provision of contract services to other biotechnology and pharmaceutical companies. Formycon AG is located in Planegg, Bayern, Germany and is part of the Biotechnology Research Services Industry. Formycon AG has 100 total employees across all of its locations and generates $36.68 million in sales (USD). There are 3 companies in the Formycon AG corporate family. Formycon AG is located in Planegg, Bayern, Germany and is part of the Biotechnology Research Services Industry. Formycon AG has 100 total employees across all of its locations and generates $36.68 million in sales (USD). There are 3 companies in the Formycon AG corporate family.
